Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (29)
Iris-Katharina Penner & H. Schreiber. 2023. Fatigue in Multiple Sclerosis. Fatigue in Multiple Sclerosis
161
177
.
Arielle Kasindi, Dieu-Trang Fuchs, Yosef Koronyo, Altan Rentsendorj, Keith Black & Maya Koronyo-Hamaoui. (2022) Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation. Cells 11:9, pages 1578.
Crossref
Crossref
Iman Adibi, Mehdi Sanayei, Farinaz Tabibian, Neda Ramezani, Ahmad Pourmohammadi & Kiarash Azimzadeh. (2022) Multiple sclerosis-related fatigue lacks a unified definition: A narrative review. Journal of Research in Medical Sciences 27:1, pages 24.
Crossref
Crossref
Jannis Achenbach, Carsten Saft, Simon Faissner & Gisa Ellrichmann. (2022) Positive effect of immunomodulatory therapies on disease progression in Huntington’s disease? Data from a real-world cohort. Therapeutic Advances in Neurological Disorders 15, pages 175628642211097.
Crossref
Crossref
Tiziana Carandini, Mara Cercignani, Daniela Galimberti, Elio Scarpini & Marco Bozzali. (2021) The distinct roles of monoamines in multiple sclerosis: A bridge between the immune and nervous systems?. Brain, Behavior, and Immunity 94, pages 381-391.
Crossref
Crossref
Snezana Lazarevic, Ana Azanjac Arsic, Dejan Aleksic, Gordana Toncev & Svetlana Miletic-Drakulic. (2021) Depression and Fatigue in Patients With Multiple Sclerosis Have No Influence on the Parameters of Cognitive Evoked Potentials. Journal of Clinical Neurophysiology 38:1, pages 36-42.
Crossref
Crossref
I Matesic & I Marcinko. (2020) Identifying the relevant determinants of MS related fatigue: The role of the clinical indicators of disease and personality. Multiple Sclerosis and Related Disorders 42, pages 102054.
Crossref
Crossref
Michelle H. Chen, Yael Goverover, Helen M. Genova & John DeLuca. (2020) Cognitive Efficacy of Pharmacologic Treatments in Multiple Sclerosis: A Systematic Review. CNS Drugs 34:6, pages 599-628.
Crossref
Crossref
Pia M. Vidal & Rodrigo Pacheco. (2019) Targeting the Dopaminergic System in Autoimmunity. Journal of Neuroimmune Pharmacology 15:1, pages 57-73.
Crossref
Crossref
Hans-Peter Hartung, Jonas Graf & David Kremer. (2019) Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study. Journal of Neurology 267:2, pages 308-316.
Crossref
Crossref
U. K. Zettl, H. Schreiber, U. Bauer-Steinhusen, T. Glaser, K. Hechenbichler & M. Hecker. (2017) Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis. Acta Neurologica Scandinavica 136:2, pages 116-121.
Crossref
Crossref
Yvonne Benešová & Aleš Tvaroh. (2016) Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE. Therapeutic Advances in Neurological Disorders 10:1, pages 18-32.
Crossref
Crossref
Christian Veauthier, Helge Hasselmann, Stefan M. Gold & Friedemann Paul. (2016) The Berlin Treatment Algorithm: recommendations for tailored innovative therapeutic strategies for multiple sclerosis-related fatigue. EPMA Journal 7:1.
Crossref
Crossref
C. Veauthier & F. Paul. (2016) Therapie der Fatigue bei Multipler SkleroseTherapy of fatigue in multiple sclerosis. Der Nervenarzt 87:12, pages 1310-1321.
Crossref
Crossref
Tina KhorshidAhmad, Crystal Acosta, Claudia Cortes, Ted M. Lakowski, Surendiran Gangadaran & Michael Namaka. (2015) Transcriptional Regulation of Brain-Derived Neurotrophic Factor (BDNF) by Methyl CpG Binding Protein 2 (MeCP2): a Novel Mechanism for Re-Myelination and/or Myelin Repair Involved in the Treatment of Multiple Sclerosis (MS). Molecular Neurobiology 53:2, pages 1092-1107.
Crossref
Crossref
Ekaterina Dobryakova, Helen M. Genova, John DeLuca & Glenn R. Wylie. (2015) The Dopamine Imbalance Hypothesis of Fatigue in Multiple Sclerosis and Other Neurological Disorders. Frontiers in Neurology 6.
Crossref
Crossref
Christian Veauthier. (2015) Hypnotic use and multiple sclerosis related fatigue: a forgotten confounder. Sleep Medicine 16:3, pages 319.
Crossref
Crossref
Iris-Katharina Penner, Eva Catharina Sivertsdotter, Elisabeth G. Celius, Siegrid Fuchs, Karen Schreiber, Sara Berkö & Anders Svenningsson. (2015) Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness. Frontiers in Neurology 6.
Crossref
Crossref
Vikram Bhise & Lauren B. Krupp. 2015. Neuropsychiatric Symptoms of Inflammatory Demyelinating Diseases. Neuropsychiatric Symptoms of Inflammatory Demyelinating Diseases
139
165
.
Peter Joseph Jongen, Dirk Lehnick, Jan Koeman, Stephan Frequin, Dorothea Heersema, Bert Kornips, Angelique Schyns-Soeterboek, Leo H. Visser, Paul Schiphof, Anton Valkenburg & Johan Hiel. (2014) Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study. Journal of Neurology 261:8, pages 1469-1476.
Crossref
Crossref
Naghmeh Mokhber, Amir Azarpazhooh, Elias Orouji, Stephen M. Rao, Bita Khorram, Mohammad Ali Sahraian, Mohsen Foroghipoor, Morteza Modares Gharavi, Sorayya Kakhi, Karim Nikkhah & Mahmoud Reza Azarpazhooh. (2014) Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: A randomized clinical trial. Journal of the Neurological Sciences 342:1-2, pages 16-20.
Crossref
Crossref
H. Z?phir. (2014) Fatigue et scl?rose en plaques. Pratique Neurologique - FMC 5:1, pages 49-56.
Crossref
Crossref
Dian He, Yun Zhang, Shuai Dong, Dongfeng Wang, Xiangdong Gao & Hongyu Zhou. (2013) Pharmacological treatment for memory disorder in multiple sclerosis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Dian He, Kai Han, Xiangdong Gao, Shuai Dong, Lan Chu, ZhanHui Feng & Shan Wu. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Anders Svenningsson, Eva Falk, Elisabeth G. Celius, Siegrid Fuchs, Karen Schreiber, Sara Berkö, Jennifer Sun, Iris-Katharina Penner & for the TYNERGY trial investigators. (2013) Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting. PLoS ONE 8:3, pages e58643.
Crossref
Crossref
Benzi M. KlugerLauren B. KruppRoger M. Enoka. (2013) Fatigue and fatigability in neurologic illnesses. Neurology 80:4, pages 409-416.
Crossref
Crossref
Lena Melamud, Daniel Golan, Rafael Luboshitzky, Idit Lavi & Ariel Miller. (2012) Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. Journal of the Neurological Sciences 314:1-2, pages 37-40.
Crossref
Crossref
Dian He, Hongyu Zhou, Duan Guo, Zilong Hao & Bo Wu. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
M.P. NamakaD.A. TurcotteM. KlowakC.M. LeongA. GrossberndtJ-A. Le DorzeM.E. ProutS. AndresenL. VuongM.J. MelansonE.E. FrostM. Doupe. (2017) Early Mitoxantrone-Induced Cardiotoxicity Detected in Secondary Progressive Multiple Sclerosis. Clinical Medicine Insights: Therapeutics 3, pages CMT.S7586.
Crossref
Crossref